acute coronary syndrome
TRANSCRIPT
![Page 1: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/1.jpg)
Acute Coronary Syndromes
![Page 2: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/2.jpg)
ACS: Definition
• A spectrum of clinical diagnoses comprising unstable angina, Non-STEMI, and STEMI that share similar pathological features involving intracoronary thrombosis
![Page 3: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/3.jpg)
ACS: Definition
From: Braunwald’s Heart Disease
![Page 4: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/4.jpg)
Pathophysiology• atherosclerosis with superimposed coronary thrombosis
• Slowly growing high-grade stenoses can progress to complete occlusion but do not usually precipitate acute STEMI d/t collateral circulation
• During development of plaques, abrupt transition can occur, resulting in
• Platelet activation
• Thrombin generation
• Thrombus formation
• Blood flow occlusion leads to imbalance between supply and demand and could lead to myocardial necrosis
• Pts with non-transmural infarction more likely to have more significan stenosis in IRA
• Less severe stenosis with lipid-laden plaques and fragile caps more likely to rupture and causing thrombsis and STEMI
![Page 5: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/5.jpg)
PathophysiologyStable Angina•Progressive narrowing of coronary lumen•Stable fibrous cap
Unstable Angina•Progressive narrowing•Acute worsening of coronary lumen due to thrombus formation
NSTEMI•Acute worsening of coronary lumen due to thrombus formation•Sub-occlusive/transient coronary thrombus with myocardial necrosis
STEMI•Minimal prior narrowing of coronary lumen•Acute rupture of thin fibrous cap•Occlusive thrombus formation•Acute injury pattern•Myocardial necrosis
![Page 6: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/6.jpg)
ACS Evaluation
![Page 7: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/7.jpg)
Angina• Definition: Discomfort in the chest/ “choking,” that
characteristically comes on with exertion, relieved by rest and/or NTG
Favors Ischemic Origin
Against Ischemic Origin
Character Constricting
Squeezing
Burning
Heaviness
Dull ache
Knife-like, sharp
Jabs
Pleuritic
Location Substernal
Anterior thorax
Arms, shoulders
Neck, teeth,
Interscapular
Left submammary area
Left hemithorax
Provoking Factors
Exertion
Excitement
Cold, meals, stress
Pain after completion of exercise
Pain with movement
![Page 8: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/8.jpg)
NormalNormalElevated cardiac TnI, TnT or CK-MB
Cardiac Marker
T wave flattening or inversion in leads with dominant R wave
Normal EKG
Fixed Q waves
Abnormal ST segments or T waves not documented to be new
New or presumably new, transient ST segment deviation (≥0.05mV) or T wave inversion (≥0.2mV) with symptoms
EKG
Chest discomfort reproduced by palpation or respiration
Extracardiac vascular disease
Transient MR, hypotension, diaphoresis, pulmonary edema or rales
Exam
Probable ischemic symptoms in absence of the intermediate likelihood characteristics
Recent cocaine use
Chest or left arm pain or discomfort as chief symptom
Age > 70
Male gender
Diabetes mellitus
Chest or left arm pain or discomfort as chief symptom reproducing prior documented angina
Known history of CAD, including MI
History
LowIntermediateHighFeature
Likelihood that signs & symptoms represent an ACS secondary to CAD
Braundwald 1994 AHCPR Publication No. 94-0602
![Page 9: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/9.jpg)
Chest Pain Classification
• Substernal• Exertional• Relieved with rest
• Interpretation – Typical Angina: 3 criteria from above – Atypical Angina: 2 criteria from above – Non-Anginal Chest Pain: 1 or less criteria from
above
![Page 10: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/10.jpg)
Classification of Angina
• STABLE vs UNSTABLE
• CCS Classification for STABLE Angina
– I: No symptoms, or angina with strenuous exertion
– II: Slight limitation of ordinary physical activity
• Walking more than two blocks, climbing more than one flight of stairs brings on angina
– III: Marked limitation of ordinary physical activity
• Walking less than two blocks, climbing less than one flight of stairs
– IV: Any physical activity brings on angina; angina at rest
![Page 11: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/11.jpg)
UA/NSTEMI 9/00
UA/NSTEMITHREE PRINCIPAL PRESENTATIONS
Rest Angina* Angina occurring at rest and prolonged, usually > 20 minutes
New-onset Angina New-onset angina of at least CCS Class III severity
Increasing Angina Previously diagnosed angina that hasbecome distinctly more frequent, longer in duration, or lower in threshold (i.e., increased by > 1 CCS)class to at least CCS Class III severity.
Rest Angina* Angina occurring at rest and prolonged, usually > 20 minutes
New-onset Angina New-onset angina of at least CCS Class III severity
Increasing Angina Previously diagnosed angina that hasbecome distinctly more frequent, longer in duration, or lower in threshold (i.e., increased by > 1 CCS)class to at least CCS Class III severity.
BraunwaldCirculation 80:410; 1989BraunwaldCirculation 80:410; 1989
* Pts with NSTEMI usually present with angina at rest.* Pts with NSTEMI usually present with angina at rest.
UA/NSTEMI 9/00
UA/NSTEMITHREE PRINCIPAL PRESENTATIONS
Rest Angina* Angina occurring at rest and prolonged, usually > 20 minutes
New-onset Angina New-onset angina of at least CCS Class III severity
Increasing Angina Previously diagnosed angina that hasbecome distinctly more frequent, longer in duration, or lower in threshold (i.e., increased by > 1 CCS)class to at least CCS Class III severity.
Rest Angina* Angina occurring at rest and prolonged, usually > 20 minutes
New-onset Angina New-onset angina of at least CCS Class III severity
Increasing Angina Previously diagnosed angina that hasbecome distinctly more frequent, longer in duration, or lower in threshold (i.e., increased by > 1 CCS)class to at least CCS Class III severity.
BraunwaldCirculation 80:410; 1989BraunwaldCirculation 80:410; 1989
* Pts with NSTEMI usually present with angina at rest.* Pts with NSTEMI usually present with angina at rest.
![Page 12: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/12.jpg)
Pre-Test Likelihood of CAD
Nonanginal pain Atypical angina Typical angina Age (y.)
Men Women Men Women Men Women
30-39
4 2 34 12 76 26
40-49
13 3 51 22 87 55
50-59
20 7 65 31 93 73
60-69 27 14 72 51 94 86
Diamond and Forrester, NEJM, 1979
![Page 13: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/13.jpg)
Relationship of Rise in Biochemical Markers to Onset of AMI
![Page 14: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/14.jpg)
Troponin
• cTnT (33 kDa) binds to tropomyosin to complex molecule to thin filament
• cTnI (24kDa) inhibits actin-myosin interactions
• cTnC binds Ca2+
• Generally not detectable in plasma of normal persons
![Page 15: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/15.jpg)
Troponin• TnT and TnI have different amino acid sequence in cardiac
vs. skeletal muscle– Permits development of cardiac specific antibodies
• More sensitive and specific than CKMB– Detects minimal amounts of cardiac necrosis (neg. CKMB)
• “minor myocardial damage/microinfarction”– Elevated in MI (pos. CKMB)– New guidelines suggest troponin is sufficient to dx MI
• Other situations assoc. with increased troponin:• CHF• ICU• Renal failure• CVA• Myocarditis/other myocardial injury
![Page 16: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/16.jpg)
Changes in Focus on Heart FailureTROPONIN I LEVELS PREDICT THE RISK OF MORTALITY IN UA/NSTEMITROPONIN I LEVELS PREDICT THE RISK OF MORTALITY IN UA/NSTEMI
1.01.0
1.71.7
3.43.4
3.73.7
6.06.0
7.57.5
00
22
44
66
88
0 to <0.40 to <0.4 0.4 to <1.00.4 to <1.0 1.0 to <2.01.0 to <2.0 2.0 to <5.02.0 to <5.0 5.0 to <9.05.0 to <9.0 >9.0>9.0
831 174 148 134 6750
Cardiac Troponin I (ng/ml)Risk Ratio 1. 1. 3.5 3.9 6.2 7.8
Antman N Engl J Med. 335:1342, 1996
Cardiac Troponin I (ng/ml)Risk Ratio 1. 1. 3.5 3.9 6.2 7.8
Antman N Engl J Med. 335:1342, 1996
Mo
rtal
ity
at
42 D
ays
(%
of
pat
ien
ts)
Mo
rtal
ity
at
42 D
ays
(%
of
pat
ien
ts)
![Page 17: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/17.jpg)
2.02.0
6.46.4
3.33.3
1.71.7
6.96.9
5.05.0
00
11
22
33
44
55
66
77
19931993 10571057 RRRR 16411641 792792 RRRR
Total MortalityTotal Mortality Cardiac MortalityCardiac Mortality
66
PTSPTS
77No. TrialsNo. TrialsTrop.Trop. Neg PosNeg Pos Neg PosNeg Pos
TROPONINS T AND IAS PREDICTORS OF MORTALITY
TROPONINS T AND IAS PREDICTORS OF MORTALITY
![Page 18: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/18.jpg)
N Engl J Med 1997;337:1648-53
Prognostic Significance of Cardiac Troponin
![Page 19: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/19.jpg)
Risk Stratification of Patients with ACS in ER
![Page 20: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/20.jpg)
US/NSTEMI Rx
![Page 21: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/21.jpg)
Management of UA/NSTEMI• 8 medication • Oxygen• ASA , clopidogrel • Anticoagulant: UFH, LMWH• Nitrates for pain
– Nitropatch 0.4 mg/hr x 12 hours daily– IV NTG
• Beta-blocker– Metoprolol 25-50 mg PO BID
• + Calcium channel blocker• ACEI for secondary prevention• Statin
• Investigations:– Serial cardiac enzymes– Definitive in-hospital risk stratification.
![Page 22: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/22.jpg)
Platelet Inhibitors in the ACS
• “A platelet GpIIb/IIIa receptor antagonist should be administered, in addition to ASA and UFH, to patients with continuing ischemia or with other high risk features—”
• “Level of the evidence: A”
ACC/AHA Guideline Circulation 2000;102:1193-1209
![Page 23: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/23.jpg)
DEATH OR MI AT 30 DAYSP
erce
nt
of
Pat
ien
ts 10.9
1.8
9
4.8
10.1
3.6
14.1
3.9
10.2
5.9
16.7
11.6
0
2
6
10
14
18
EPIC CAPTURE EPILOG EPISTENT PRISM-PLUS PURSUIT
Placebo GP IIb-IIIa Inhibitor
ACC SlideACC Slide
![Page 24: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/24.jpg)
ANTIPLATELET Rx
Class I
Definite ACS with continuingPossible ACS Likely/Definite ACS Ischemia or Other High-Risk
Features or planned PCI
Aspirin Aspirin Aspirin++ ++
Subcutaneous LMWH IV heparinor
IV heparin IV platelet GP IIb/IIIa antagonist++
ACC Slide
![Page 25: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/25.jpg)
Primary efficacy endpoints in the CURE trial
18.8%
11.4%
Placebo
<0.0010.8616.4% CV death/MI/stroke/refractory ischemia
<0.0010.809.3%CV death/MI/stroke
p valueRelative risk
ClopidogrelEndpoint
The CURE Investigators. N Engl J Med 2001;345: 494 -502.
Other Antiplatelet Agents: Clopidogrel
Role at this point in combination with 2b3a inhibitorunclear: a useful option in ASA allergic pt’
.
![Page 26: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/26.jpg)
Bleeding results
1.8%
2.7%
Placebo
0.132.1%Life-threatening bleeding
0.0013.7%Major bleeding
p valueClopidogrelEndpoint
The CURE Investigators. N Engl J Med 2001;345: 494-502.
Effect of Clopidogrel in ACS: the CURE trial
![Page 27: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/27.jpg)
In Hospital Risk Stratification with ACS: Principles
• Spectrum of risk
• Features associated with poor prognosis (high probability of short term MI, etc.)– EKG features: dynamic ST depression– Cardiac markers: increased troponin
• Risk stratification refers to identifying patients at risk
![Page 28: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/28.jpg)
Strategies for Risk Stratification
• Non-invasive– EST
• Sensitivity 70%• Specificity 70%
– MIBI scan• Sensitivity 86-90%• Specificity 90%
• Invasive– Diagnostic coronary angiography
![Page 29: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/29.jpg)
Exercise Stress Testing– Positive response: horizontal 1mm ST depression and
symptoms– High risk response:
• Deep ST depression• Poor exercise tolerance: unable to exercise past stage 2 (<6
mins)• Exercise induced hypotension and dysrhythmias
– Uninterpretable:• LBBB• Digoxin• LVH
– Contra-indications:• Severe Aortic stenosis• Aortic dissection• MI/ACS within 24 h• PE
![Page 30: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/30.jpg)
Angiography• Gold standard
– Defines anatomy: 1VD, 2VD, 3VD, LM– Assesses LV function– Guides treatment: PCI, CABG or medical therapy
• Indications– UA/post MI with ongoing pain, ST depresssion– Hemodynamic instability– CHF, ventricular arrhythmias– Previous PCI, CABG– High risk non-invasive test– Emerging as the strategy of choice for initial evaluation of most
ACS with elevated troponins or EKG changes• Based on FRISC II, TACTICS trials
• Strategy needs to be individualized.
![Page 31: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/31.jpg)
Angiography
![Page 32: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/32.jpg)
Indications for Invasive Risk Stratification Strategy in UA/NSTEMI
• Class I– Recurrent ischemia at rest despite medical Rx– Elevated troponin I or T– New ST depression– High risk findings on non-invasive testing– Depressed LV function– Hemodynamic instability– Sustained VT– PCI within 6 months– Prior CABG
• In the absence of the above, either non-invasive or invasive strategy can be followed.
ACC/AHA Guidelines for Management of UA/NSTEMI 2002
![Page 33: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/33.jpg)
SUMMARY: ER Evaluation of Patient with Chest Pain
Symptoms Suggestive of
Cardiac Origin?
Consider Alternative Diagnosis
Stable Unstable
NO YES
Early Risk Stratification in ER
![Page 34: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/34.jpg)
SUMMARY: Management of UA/NSTEMIHIGH RISK (12-30%)*
•Prolonged CP (>20 minutes or ongoing), plus:•EKG:
•Transient ST changes•Sustained ST depr.•Deep T wave inv. (>5 leads)
•Biochemical markers:•Troponin/CKMB abnormal
•Recurrent ischemia•AMI in last 4 weeks•Hemodynamic compromise
INTERM. RISK(4-8%)
•No high risk features but >=1 of:
•Ongoing chest pain•Crescendo angina•Borderline positive troponin I (0.4-2.0)•Previous intervention: PCI or CABG•Increased baseline risk (DM, elderly)
LOW RISK(<2%)
•No high or intermediated features•Chest pain, single episode, exertional•EKG: normal or nonspecific or unchanged
•May include previous hx of CAD or risk factors
•ASA + heparin/LMWH•GP IIb/IIIa•Early cardiac cath
•ASA + clopidogrel•UFH or LMWH•Cardiac cath lab
•ASA•No heparin•Observe/outpt tests
*30
day
rate
of d
eath
or
MI
![Page 35: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/35.jpg)
STEMI
• WHO defn: 2 of – characteristic chest pain– ECG changes – ST elevation– Biochemical changes
• ACC + ESC– Rise and fall of biochemical marker (Tn, CK-MB) +
one of • ischemic symptoms• development of pathological Q waves• ECG changes suggestive of ischemia• Coronary angiography
![Page 36: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/36.jpg)
STEMI
• More than 1 million MI’s per year in US
• Fatal in 1/3 of pts, ½ of death occurs within 1 hr of symptoms (arrhythmias)
![Page 37: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/37.jpg)
Symptoms• prolonged pain > 30 min usually• constricting, crushing, or compressing; heaviness or
squeezing• can be choking, burning, knife-like• retrosternal, radiating to L>R side of chest, ulnar sides of
arms L>R, shoulder, upper extremity, jaw, neck, interscapular region sometimes epigastric
• pain usually implies ischemia• other sx
– nausea/vomiting more common in inferior MI – weakness– dizziness– palpitation– cold perspiration– sense of impending doom
![Page 38: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/38.jpg)
STEMI
• Pre-hospital care– EMS
• Dispatch, first response, EMS ambulance
• AED to first responders
• Relief of pain to reduce sympathetic tone
• Rapid transfer to hospital
– Prehosp fibrinolysis• Some evidence suggesting improved mortality
![Page 39: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/39.jpg)
STEMI
• ER Management– Early recognition
• Ischemic type chest pain• ECG signs
– ECG monitor rhythm– IV access– O2– Reperfusion strategy will depend on
• Time since symptoms• Risk assoc with STEMI• Risk of lytics• Time required for PCI
![Page 40: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/40.jpg)
Time to Rx
![Page 41: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/41.jpg)
STEMI - Acute Rx• ASA
– Block formation of thromboxane A2 in platelets by blocking cox– Chew 160-325 mg to allow for buccal absorption
• Pain control– Try to decrease sympathetic activity– Analgesics– Nitrates
• Coronary vasodilation, decrease preload by increasing venous capacitance
• Avoid if suspect RV infarct– Beta blockers
• Reduce HR, decrease myocardial oxygen demand• Reduce pain• Reduce the need for analgesics• Reduce infarct size
– Oxygen
![Page 42: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/42.jpg)
STEMI - Reperfusion
• “Time is muscle”• Increased mortality with delay in reperfusion
regardless of strategy• Less time:
– Recovery of LV systolic fxn– Improved diastolic dysfxn– Reduced mortality– Post ischemic contractile dysfxn can occur after
reperfusion– Myocardial stunning
![Page 43: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/43.jpg)
STEMI - Lytics
• Benefits– Recanalize thrombotic occlusion– Restores coronary flow– Reduce infarct size– Improves myocardial function– Improves survival– May result in microvascualr damage and
reperfusion injury– STR strong predictor of reperfusion
![Page 44: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/44.jpg)
STEMI - lytics
• GISSI first trial to demonstrate benefit of streptokinase
• Other fibrinolytics– Alteplase (t-PA)
• GUSTO I
– Reteplace (rtPA)• GUSTO III (equivalence)
– Tenecteplase (TNK)• ASSENT II (equiv with t-PA)
![Page 45: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/45.jpg)
Evidence for Fibrinolysis: GISSI
n >11,000
ARR: 2%
RRR: 18%
Circ. 1998
![Page 46: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/46.jpg)
Comparison of Thrombolytics: GUSTO
n=>41,000
ARR 0.9%RRR 12.5%
NEJM, 1993
![Page 47: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/47.jpg)
ASSENT 2
• N= 16949
• Design: non-inferiority
• Trend toward decrease in bleeding
• Improve ease of use with Bolus infusion
• Combination with heparin IV
Lancet 1999; 354: 716-22
![Page 48: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/48.jpg)
Time to Rx
![Page 49: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/49.jpg)
Efficacy of Thrombolysis: Subgroups
FibrinolyticTherapy Trialists’ Group.Lancet, 1988
n=56,800
![Page 50: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/50.jpg)
Choosing a Fibrinolytic
• Patients in whom t-PA is proven superior to SK:– Age < 75– Anterior MI, presenting within 4 hours– High risk/extensive MI at other site within 4 hours– Cardiogenic shock– Previous SK exposure
• TNK = rtPA > tPA
– Easy administration
– Lower chance of med error
– Less non-cerebral bleeds• Patients in whom SK appears to be equivalent to t-PA:
– Inferior, posterior or lateral MI– MI at any site after 6 hours– Age > 75 years
![Page 51: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/51.jpg)
Bleeding complications with Lytics
• Major bleeding 0.5-2%
• Minor bleeding: 10-20 %
• Intracranial hemorrhage: 0.5-2%
• Management:– D/C thrombolytic– Cryoprecipitate (fibrinogen enriched)– If heparin, give protamine sulfate
![Page 52: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/52.jpg)
Indications for Primary PCI
• Class I– Alternative to thrombolytic if performed in a timely fashion by skilled
individuals– Patients within 36 hours of AMI, with cardiogenic shock, <75 years
• Class IIa– Contraindication to thrombolysis
• Class IIb– NSTEMI within 12 hours, with less than TIMI II flow in infarct
related artery• Class III
– Elective PCI of non-IRA at time of AMI– Beyond 12 hours of symptoms, no evidence of ischemia– Successful thrombolysis
From ACC/AHA Guidelines, 2000
![Page 53: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/53.jpg)
STEMI -PCI
• Meta analyis shows improved clinical endpoints favoring PCI– Factors to consider
• Time to treatment
• Risk of STEMI
• Cardiogenic shock
• Kilip class >= II
• Risk of bleeding
• Time to transport to skilled PCI center
![Page 54: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/54.jpg)
STEMI – Other Rx• ASA
– ISIS-2• Thienpyridines
– Clopidogrel• CLARITY
– Ticlopidine• Inhibit binding to adenosine diphosphate receptor
• GPIIb/IIIa inhibitors– Abciximab– Tirofiban– Eptifibatide
• GUSTO V– rtPA vs 1/2rtPA and abciximab– similar efficace endpoints but increased bleeds with IIb/IIIa
![Page 55: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/55.jpg)
ASA: ISIS 2
Lancet, 1988
n > 17, 000
![Page 56: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/56.jpg)
STEMI – Other Rx
• Heparin – reduces reinfarction, stroke, PE– reduces mortality in pts receiving lytic
• LMWH– ASSENT III showed benefit over UFH in pts
receiving TNK
• Others– Bivalirudin (HITT)
![Page 57: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/57.jpg)
Post- STEMI Rx• BB • ACEi
– Prevents ventricular remodeling– Improved hemodynamics– Reduces CHF– Selected population: (long-term, started day 3-16)
• SAVE• AIRE• TRACE
– Unselected pop (short term, started early)• GISSI 3• SMILE• ISIS-4• CCS-1
![Page 58: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/58.jpg)
Post- STEMI Rx
• ARB – OPTIMAAL (losartan)– VALIANT (valsartan)
• Aldasterone antagonists– EPHESUS (acute MI, LV dysfxn, HF)– Reduction in mortality
• Statins– PROVE-IT
![Page 59: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/59.jpg)
Variable VSD Free Wall Rupture
Papillary Muscle Rupture
Age 63 69 65
Days, post MI 3-5 3-6 3-5
Anterior MI 66% 50% 25%
New Murmur 90% 25% 50%
Thrill Yes No Rare
Previous MI 25% 25% 30%
Echo: VSD Pericardial Effusion
Flail leaflet
MR
PA catheter: O2 step-up RA-RV
Equalization of diastolic press.
Prominent V-wave
Mortality:
Medical
Surgical
90%
50%
90%
?
90%
40-90%
Mechanical Complications of MI
![Page 60: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/60.jpg)
Other Complications
• Arrhythmias– Electrical instability
• VPB• VT• VF• AIVR
– Pump failure/inc symp drive• Sinus tachy• AFib/Flutter• SVT
– Brady/conduction• Sinus brady• Junctional escape• AVB
![Page 61: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/61.jpg)
Other Complications
• Recurrent chest pain– Distinguish reinfarction from recurrent
ischemia from non-ischemic chest pain
• Pericarditis
• LV aneurysm
![Page 62: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/62.jpg)
Risk Stratification
• survival after STEMI depends on– LV fxn
• Stress/pharma Echo, PET
– Residual potentially ischemic myocardium• Submaximal ETT
– Susceptibility to vent arrhythmias
![Page 63: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/63.jpg)
Risk Stratification
![Page 64: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/64.jpg)
Discharge Planning
• usually 5 days post STEMI
• counseling– ambulation but avoid heavy lifting– graded activity (symptom limited)– Rehabilitation
![Page 65: Acute coronary syndrome](https://reader033.vdocuments.net/reader033/viewer/2022060107/554b4084b4c905cd2c8b4bda/html5/thumbnails/65.jpg)
Questions